Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. COVID and CopMich: comparing and contrasting COVID-19 experiences in the USA and Scandinavia

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Oxytocin antagonists: the next frontier in PE treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clarifying the link between ibuprofen and hypogonadism

    Publikation: Bidrag til tidsskriftReviewpeer review

  5. From separation to collaboration: the future of urology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Age-related changes in human Leydig cell status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Does height and IGF-I determine pubertal timing in girls?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of psychological stress measured in three different scales on testis function: A cross-sectional study of 1362 young men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Testicular germ cell tumours (TGCTs) are the most frequent cancer type in young men and originate from the common precursor germ cell neoplasia in situ (GCNIS). For decades, clinical management of patients with TGCT has relied on classic serum tumour markers: α-fetoprotein, human chorionic gonadotropin subunit-β and lactate dehydrogenase. In the past 10 years, microRNAs have been shown to outperform classic serum tumour markers in the diagnosis of primary tumours and in follow-up monitoring and prediction of relapse. miR-371a-3p is the most consistent marker and exhibits >90% diagnostic sensitivity and specificity in TGCT. However, miR-371a-3p cannot be used to diagnose GCNIS or mature teratoma. Future efforts must technically standardize the microRNA-based methods internationally and introduce miR-371a-3p as a molecular liquid biopsy-based marker for TGCTs in the clinic.

OriginalsprogEngelsk
TidsskriftNature reviews. Urology
Vol/bind17
Udgave nummer4
Sider (fra-til)201-213
Antal sider13
ISSN1759-4812
DOI
StatusUdgivet - apr. 2020

ID: 59983847